Latest On OraSure Technologies, Inc (OSUR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-17 06:43 EST | News | OraSure: Valuation Upside On The Table At 16x Forward P/E | N/A |  |
| 2023-05-16 03:11 EST | News | OraSure Technologies: As Good As It Gets | N/A | |
| 2023-05-11 09:05 EST | News | OraSure Technologies, Inc. (OSUR) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 19:14 EST | News | OraSure Technologies Non-GAAP EPS of $0.47 beats by $0.31, revenue of $154.96M beats by $28.39M | N/A | |
| 2023-05-10 05:58 EST | News | OraSure Technologies Q1 2023 Earnings Preview | N/A | |
About OraSure Technologies, Inc (OSUR):
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. read more...It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
General
- Name OraSure Technologies, Inc
- Symbol OSUR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- Full Time Employees 570
- Last Split Factor3:1
- Last Split Date1987-04-08
- Fiscal Year EndDecember
- IPO Date1986-11-12
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Gic SubIndustryHealth Care Supplies
- Web URLhttp://www.orasure.com
Valuation
- Trailing PE 51.35
- Price/Sales (Trailing 12 Mt.) 3.93
- Price/Book (Most Recent Quarter) 1.81
- Enterprise Value Revenue 3.01
- Enterprise Value EBITDA 150.14
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.51
- Next Year EPS Estimate $0.63
- Next Quarter EPS Estimate $0.09
- Profit Margin -9%
- Operating Margin -3%
- Return on Assets -1%
- Return on Equity -4%
- Revenue 171.65 million
- Earnings Per Share $0.20
- Revenue Per Share $2.54
- Gross Profit 101.8 million
- Quarterly Earnings Growth 26.7%
Highlights
- Market Capitalization 800.75 million
- EBITDA 3.5 million
- PE Ratio 12.36
- PEG Ratio 2.3
- Analyst Target Price $18
- Book Value Per Share $5.56
Share Statistics
- Shares Outstanding 71.73 million
- Shares Float 70.79 million
- % Held by Insiders 149%
- % Held by Institutions 101%
- Shares Short 6.69 million
- Shares Short Prior Month 6.11 million
- Short Ratio 6.7
- Short % of Float 11%
- Short % of Shares Outstanding 9%
Technicals
- Beta -0.15
- 52 Week High $19.75
- 52 Week Low $6.45
- 50 Day Moving Average 12.33
- 200 Day Moving Average 12.6
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
OraSure Technologies, Inc (OSUR) Dividend Calendar:
OraSure Technologies, Inc (OSUR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
OraSure Technologies, Inc (OSUR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
OraSure Technologies, Inc (OSUR) Chart:
OraSure Technologies, Inc (OSUR) News:
Below you will find a list of latest news for OraSure Technologies, Inc (OSUR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
OraSure Technologies, Inc (OSUR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest OSUR Trades:
OraSure Technologies, Inc (OSUR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-04 | 8-K (Current report) | |
| 2020-09-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-01 | 8-K (Current report) | |
| 2020-08-26 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-25 | 8-K (Current report) | |
| 2020-08-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-04 | 8-K (Current report) | |
| 2020-06-03 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-02 | 8-K (Current report) | |
| 2020-06-02 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-02 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-19 | 8-K (Current report) | |
OraSure Technologies, Inc (OSUR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of OraSure Technologies, Inc (OSUR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 149%
Institutional Ownership: 10100%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-25 | James A Datin | Director | Buy | 1,492.00 | 10.89 | 16,247.88 | 17,695.00 | |
| 2020-06-23 | James A Datin | Director | Buy | 1,667.00 | 9.74 | 16,244.08 | 16,658.00 | |
| 2020-06-01 | Lelio Marmora | Director | Buy | 7,015.00 | 14.26 | 99,998.83 | 7,015.00 | |
| 2020-05-18 | David Shulkin | Director | Buy | 6,577.00 | 15.97 | 105,001.81 | 15,542.00 | |
| 2020-05-18 | James A Datin | Director | Buy | 6,577.00 | 15.97 | 105,001.81 | 21,568.00 | |
| 2020-05-18 | RONNY B LANCASTER | Director | Buy | 6,577.00 | 15.97 | 105,001.81 | 23,830.00 | |
| 2020-05-18 | Mara G. Aspinall | Director | Buy | 6,577.00 | 15.97 | 105,001.81 | 26,760.00 | |
| 2020-05-18 | EAMONN P HOBBS | Director | Buy | 6,577.00 | 15.97 | 105,001.81 | 34,355.00 | |
| 2020-05-18 | Michael Celano | Director | Buy | 8,143.00 | 15.97 | 130,003.00 | 66,942.00 | |
| 2020-05-11 | Lisa Nibauer | EVP & BU Lead - Infectious | Buy | 14,071.00 | 17.77 | 250,006.49 | 14,071.00 | |
| 2020-04-08 | James A Datin | Director | Buy | 2,145.00 | 10.61 | 22,747.73 | 15,577.00 | |
| 2020-04-06 | David Shulkin | Director | Buy | 8,965.00 | 11.16 | 100,004.58 | 8,965.00 | |
| 2020-02-01 | Kathleen Gallagher Weber | EVP & BU Lead - Molecular | Buy | 10,238.00 | 7.17 | 73,355.27 | 102,229.00 | |
| 2020-02-01 | Kathleen Gallagher Weber | EVP & BU Lead - Molecular | Buy | 10,238.00 | 7.17 | 73,355.27 | 109,444.00 | |
| 2020-02-01 | JACK E JERRETT | SVP & General Counsel | Buy | 35,813.00 | 7.17 | 256,600.15 | 120,837.00 | |
| 2020-02-01 | JACK E JERRETT | SVP & General Counsel | Buy | 11,193.00 | 7.17 | 80,197.85 | 132,030.00 | |
| 2020-02-01 | JACK E JERRETT | SVP & General Counsel | Buy | 11,195.00 | 7.17 | 80,212.18 | 138,375.00 | |
| 2020-02-01 | Michele Marie Miller | VP, Finance and Controller | Buy | 7,545.00 | 7.17 | 54,059.93 | 14,861.00 | |
| 2020-02-01 | STEPHEN S PHD TANG | President and CEO | Buy | 84,997.00 | 7.17 | 609,003.51 | 199,763.00 | |
| 2020-02-01 | II Anthony Zezzo | EVP & BU Lead - Infectious | Buy | 34,698.00 | 7.17 | 248,611.17 | 209,753.00 | |